IMMIX BIOPHARMA INC (IMMX)

US45258H1068 - Common Stock

3.07  0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

IMMIX BIOPHARMA INC

NASDAQ:IMMX (3/28/2024, 8:17:25 PM)

3.07

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap77.18M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

IMMX Daily chart

Company Profile

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 9 full-time employees. The company went IPO on 2021-12-16. Its lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously) and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging its TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Its TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its other drug candidates include IMX-111 and IMX-120. IMX-111 and IMX-120 are under development for colorectal cancer and inflammatory bowel disease.

Company Info

IMMIX BIOPHARMA INC

11400 West Olympic Blvd., Suite 200

Los Angeles CALIFORNIA

P: 18889581084

Employees: 9

Website: https://www.immixbio.com/

IMMX News

News Image9 days ago - Immix Biopharma, Inc.Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
News Image9 days ago - Immix Biopharma, Inc.Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a...

News Image24 days ago - Immix Biopharma, Inc.Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words

News Image24 days ago - Immix Biopharma, Inc.Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words...

News Imagea month ago - Immix Biopharma, Inc.Immix Biopharma 12 Month Review Progress Update

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell...

News Image2 months ago - Immix Biopharma, Inc.Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

IMMX Twits

Here you can normally see the latest stock twits on IMMX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example